At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 319 enrolled
Drug / intervention
Afatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung
In Brief
A Phase 2 clinical trial evaluating Afatinib and gefitinib for Lung Neoplasms. Completed, enrolled 319 participants across 63 sites in 14 countries.
Detailed Summary
This is a randomised, open-label, phase IIb trial of afatinib to compare to gefitinib in first-line treatment setting with patients who are having epidermal growth factor receptor mutation positive advanced adenocarcinoma of the lung.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Neoplasms
CountriesAustralia, Canada, China, France, Germany, Hong Kong, Ireland, Norway, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionApr 2016
Study CompletionApr 2019
TodayJul 2026
First PostedNov 8, 2011
Enrollment StartDec 13, 2011
Primary CompletionApr 8, 2016
Study CompletionApr 12, 2019
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.7 years ago
Interventions
Afatinibdrug
afatinib once daily
gefitinibdrug
Gefitinib once daily